Literature DB >> 26081245

Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.

Sheldon M Singh1, Harindra C Wijeysundera.   

Abstract

Recently, novel oral anticoagulants (NOACs) have been approved for stroke prevention in patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of warfarin, they are associated with increased costs. In this review, we will provide an overview of the cost-effectiveness of NOACs for stroke prevention in AF. Our comments and conclusions are limited to studies directly comparing all available NOACs within the same framework. The available cost-effectiveness analyses suggest that NOACs are cost-effective compared to warfarin, with apixaban likely being most favorable. However, significant limitations in these models are present and should be appreciated when interpreting their results.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26081245     DOI： 10.1007/s11886-015-0618-4

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  32 in total

1.  National Institute for Clinical Excellence and its value judgments.

Authors:  Michael D Rawlins; Anthony J Culyer
Journal:  BMJ       Date:  2004-07-24

2.  Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.

Authors:  Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

3.  Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.

Authors:  Gregory Y H Lip; Thitima Kongnakorn; Hemant Phatak; Andreas Kuznik; Tereza Lanitis; Larry Z Liu; Uchenna Iloeje; Luis Hernandez; Paul Dorian
Journal:  Clin Ther       Date:  2014-02-06       Impact factor: 3.393

Review 4.  Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation.

Authors:  Brendan L Limone; William L Baker; Elizabeth S Mearns; C Michael White; Jeffrey Kluger; Craig I Coleman
Journal:  J Clin Epidemiol       Date:  2014-07-10       Impact factor: 6.437

5.  ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines.

Authors:  Jeffrey L Anderson; Paul A Heidenreich; Paul G Barnett; Mark A Creager; Gregg C Fonarow; Raymond J Gibbons; Jonathan L Halperin; Mark A Hlatky; Alice K Jacobs; Daniel B Mark; Frederick A Masoudi; Eric D Peterson; Leslee J Shaw
Journal:  J Am Coll Cardiol       Date:  2014-03-27       Impact factor: 24.094

Review 6.  Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?

Authors:  Paul S J Miller; Fredrik L Andersson; Lalit Kalra
Journal:  Stroke       Date:  2005-01-06       Impact factor: 7.914

7.  Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.

Authors:  Robert G Hart; Lesly A Pearce; Maria I Aguilar
Journal:  Ann Intern Med       Date:  2007-06-19       Impact factor: 25.391

8.  Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.

Authors:  Sheldon M Singh; Andrew Micieli; Harindra C Wijeysundera
Journal:  Circulation       Date:  2013-05-22       Impact factor: 29.690

9.  Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.

Authors:  Carla Rognoni; Monia Marchetti; Silvana Quaglini; Nicola Lucio Liberato
Journal:  Clin Drug Investig       Date:  2014-01       Impact factor: 2.859

10.  Edoxaban versus warfarin in patients with atrial fibrillation.

Authors:  Robert P Giugliano; Christian T Ruff; Eugene Braunwald; Sabina A Murphy; Stephen D Wiviott; Jonathan L Halperin; Albert L Waldo; Michael D Ezekowitz; Jeffrey I Weitz; Jindřich Špinar; Witold Ruzyllo; Mikhail Ruda; Yukihiro Koretsune; Joshua Betcher; Minggao Shi; Laura T Grip; Shirali P Patel; Indravadan Patel; James J Hanyok; Michele Mercuri; Elliott M Antman
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245
View more
  4 in total

1.  Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding.

Authors:  Truman J Milling; Jennifer Frontera
Journal:  Am J Manag Care       Date:  2017-04       Impact factor: 2.229

2.  Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.

Authors:  Kostas Athanasakis; Eleftheria Karampli; Dimitrios Tsounis; Aikaterini Bilitou; John Kyriopoulos
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

3.  Characteristics of patients with thromboembolic disorders on warfarin therapy in resource limited settings.

Authors:  Zipporah Kamuren; Gabriel Kigen; Alfred Keter; Alice Maritim
Journal:  BMC Health Serv Res       Date:  2018-09-19       Impact factor: 2.655

Review 4.  Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians.

Authors:  W Frank Peacock; Zubaid Rafique; Adam J Singer
Journal:  Emerg Med Int       Date:  2016-05-16       Impact factor: 1.112
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.